Literature DB >> 24016507

Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial.

John H Alexander1, Elliott Levy, Jack Lawrence, Michael Hanna, Anthony P Waclawski, Junyuan Wang, Robert M Califf, Lars Wallentin, Christopher B Granger.   

Abstract

BACKGROUND: In ARISTOTLE, apixaban resulted in a 21% reduction in stroke, a 31% reduction in major bleeding, and an 11% reduction in death. However, approval of apixaban was delayed to investigate a statement in the clinical study report that "7.3% of subjects in the apixaban group and 1.2% of subjects in the warfarin group received, at some point during the study, a container of the wrong type."
METHODS: Rates of study medication dispensing error were characterized through reviews of study medication container tear-off labels in 6,520 participants from randomly selected study sites. The potential effect of dispensing errors on study outcomes was statistically simulated in sensitivity analyses in the overall population.
RESULTS: The rate of medication dispensing error resulting in treatment error was 0.04%. Rates of participants receiving at least 1 incorrect container were 1.04% (34/3,273) in the apixaban group and 0.77% (25/3,247) in the warfarin group. Most of the originally reported errors were data entry errors in which the correct medication container was dispensed but the wrong container number was entered into the case report form. Sensitivity simulations in the overall trial population showed no meaningful effect of medication dispensing error on the main efficacy and safety outcomes.
CONCLUSIONS: Rates of medication dispensing error were low and balanced between treatment groups. The initially reported dispensing error rate was the result of data recording and data management errors and not true medication dispensing errors. These analyses confirm the previously reported results of ARISTOTLE.
© 2013.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24016507     DOI: 10.1016/j.ahj.2013.05.025

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

1.  Assessing protocol adherence in a clinical trial with ordered treatment regimens: Quantifying the pragmatic, randomized optimal platelet and plasma ratios (PROPPR) trial experience.

Authors:  Hongjian Zhu; Erin E Fox; Sarah Baraniuk; John B Holcomb; Charles E Wade; Deborah J Del Junco; Barbara C Tilley
Journal:  Injury       Date:  2016-07-21       Impact factor: 2.586

Review 2.  Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.

Authors:  Miho Kimachi; Toshi A Furukawa; Kimihiko Kimachi; Yoshihito Goto; Shingo Fukuma; Shunichi Fukuhara
Journal:  Cochrane Database Syst Rev       Date:  2017-11-06

Review 3.  A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?

Authors:  Eugene Yang
Journal:  Vasc Health Risk Manag       Date:  2014-08-21

4.  Strategies implemented for accurate dispensing of an investigational new drug in a multi-site HIV prevention clinical trial.

Authors:  Cindy Jacobson; Jayajothi Moodley; Aruna Bhoola; Rebecca Sakwa; Jeeva Moodley; Jasmin Sukdao; Nivriti Hurbans; Bhavna Maharaj; Anushka Naidoo; Melanie Maclachlan; Gift Chareka; Kudzai Hlahla; Mary Chadza
Journal:  Contemp Clin Trials Commun       Date:  2021-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.